November 2012 Editor's Picks: Products from Malvern Instruments and GEA Pharma Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

November 2012 Editor's Picks: Products from Malvern Instruments and GEA Pharma Systems

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Malvern Instruments
Dynamic light scattering system measures microrheology and protein structure


The Zetasizer Nano ZSP is an addition to the Malvern Instruments’ range of dynamic light scattering (DLS) systems. The Nano ZSP measures both size and zeta potential (i.e., electrophoretic mobility) of proteins. A new protein mobility measurement type in the software that controls data acquisition guides the user through the measurement and assesses and reports on data quality. The Nano ZSP uses a new version of Zetasizer software that enables microrheology measurements for the first time on Zetasizer instruments. This DLS-based optical technique allows rheological characterization of weakly-structured and highly strain-sensitive materials using only microliter sample volumes. Applications include measuring the viscosity of polymer and protein solutions and determining the onset of protein aggregation.


GEA Pharma Systems
Continuous high-shear granulation and drying system improves efficiency


The ConsiGma continuous high-shear granulation and drying system from GEA Pharma Systems uses continuous production technology instead of traditional batch technology to produce granules. The system is about one-fourth the size of a traditional granulation line and can run from 500 g for research and development up through production-size batches. Because it is a continuous process, larger amounts do not require a larger machine, but only a longer time. Eliminating scale-up helps reduce development time and cost. ConsiGma has been shown to improve intra-granular porosity and compressibility characteristics.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Equipment and Processing Report,
Click here